Compare CLBT & STVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLBT | STVN |
|---|---|---|
| Founded | 1999 | 1949 |
| Country | Israel | Italy |
| Employees | N/A | 5521 |
| Industry | Computer Software: Prepackaged Software | Containers/Packaging |
| Sector | Technology | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 5.4B |
| IPO Year | N/A | 2021 |
| Metric | CLBT | STVN |
|---|---|---|
| Price | $17.17 | $19.88 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 2 |
| Target Price | ★ $24.40 | $23.75 |
| AVG Volume (30 Days) | ★ 788.3K | 294.8K |
| Earning Date | 02-12-2026 | 03-05-2026 |
| Dividend Yield | N/A | ★ 0.32% |
| EPS Growth | N/A | ★ 19.61 |
| EPS | 0.31 | ★ 0.60 |
| Revenue | $455,903,000.00 | ★ $1,373,219,524.00 |
| Revenue This Year | $20.25 | $8.42 |
| Revenue Next Year | $17.24 | $9.61 |
| P/E Ratio | $54.32 | ★ $33.04 |
| Revenue Growth | ★ 18.36 | 6.97 |
| 52 Week Low | $13.10 | $17.81 |
| 52 Week High | $26.30 | $28.00 |
| Indicator | CLBT | STVN |
|---|---|---|
| Relative Strength Index (RSI) | 38.39 | 38.77 |
| Support Level | $17.78 | $20.19 |
| Resistance Level | $18.80 | $21.23 |
| Average True Range (ATR) | 0.51 | 0.76 |
| MACD | -0.15 | -0.00 |
| Stochastic Oscillator | 6.03 | 0.00 |
Cellebrite DI Ltd is an Israeli digital intelligence company that provides tools for federal, state, and local law enforcement as well as enterprise companies and service providers to collect, review, analyze, and manage digital data. Some of its products include Cellebrite UFED, Cellebrite Physical Analyzer, Cellebrite UFED Cloud, Cellebrite Frontliner, Cellebrite Responder, Cellebrite Premium, and Cellebrite Seeker.
Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, the company derives majority revenue from Europe, Middle East and Africa.